Nitrilase mutant and application thereof in preparation of 1-cyanocyclohexyl acetic acid

A technology of nitrilase and mutants, which is applied in the field of preparation of antiepileptic drug gabapentin, can solve problems such as high risk, equipment corrosion, environmental pollution, etc., and achieve good application prospects and shorten the effect of reaction time

Active Publication Date: 2020-07-31
ZHEJIANG UNIV OF TECH
View PDF22 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, chemical synthesis technology is used to synthesize gabapentin and its key intermediate 1-cyanocyclohexylacetic acid, and there are problems such as serious environmental pollution, serious corrosion to equipment, and great danger in the production process.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nitrilase mutant and application thereof in preparation of 1-cyanocyclohexyl acetic acid
  • Nitrilase mutant and application thereof in preparation of 1-cyanocyclohexyl acetic acid
  • Nitrilase mutant and application thereof in preparation of 1-cyanocyclohexyl acetic acid

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Example 1: Site-directed mutagenesis and screening

[0031] 1. Mutation site selection

[0032] The present invention utilizes site-directed mutation technique to carry out site-directed mutation at 168 sites on the nitrilase coding gene (GenBank Accession no.: AHW42593.1) derived from A. facilis CCTCC NO: M 029044, and mutates into E.coli BL21(DE3) / pET-28b(+)-AcN-F168V (see Zhang X H, et al. .ProcessBiochemistry, 2014.), based on this, mainly aimed at the amino acid site on the "A surface" as the mutation site, and after the site-directed mutation was successful by using the whole plasmid PCR, the expression vector where the target gene was located was transferred into E. coli Host, after induced expression, the positive mutants were screened out by enzyme activity detection method, and the enzyme activity was repeatedly detected to determine the mutant with improved enzyme activity, so as to obtain a self-assembly tendency and be able to efficiently catalyze the regi...

Embodiment 2

[0039] Example 2: Expression of nitrilase mutants

[0040] A plasmid pET-28b(+)-AcN-F168V containing nitrilase AcN-F168V (ie, SEQ ID No.1) from Acidovorax facilis CCTCC NO:M 029044 was constructed. The constructed pET-28b(+)-AcN-F168V expression plasmid was introduced into Escherichia coli E. Coli BL21(DE3) to realize overexpression. Site-directed mutagenesis was carried out by site-directed saturation mutagenesis, and recombined into the expression vector pET-28b(+), and then the recombinant plasmid was transferred into the expression host E. Coli BL21(DE3) to construct mutants. Obtain the mutant transformant E.coli BL21(DE3) / pET-28b(+)-AcN-G180F of embodiment 1, E.coli BL21(DE3) / pET-28b(+)-AcN-G180D, E.coli BL21(DE3) / pET-28b(+)-AcN-A205C and combined mutant E.coli BL21(DE3) / pET-28b(+)-AcN-G180D / A205C, and the original strain E.coli BL21(DE3) / pET-28b(+)-AcN-F168V (see Zhang X H, et al. Activity improvement of a regioselective nitrilase from Acidovorax facilis and its appli...

Embodiment 3

[0041] Embodiment 3: the purification of nitrilase and mutant protein thereof

[0042] (1) Add binding buffer (50mM NaH 2 PO 4 , 300mM NaCl, pH 8.0), resuspended bacteria and then ultrasonically disrupted (400W, 20min, 1s break and 1s pause). After the crushed product was centrifuged (8000rpm, 15min), the supernatant was taken as a crude enzyme solution for separation and purification.

[0043] (2) After prepacking 10mL Ni-NTA affinity chromatography column, use binding buffer (50mM NaH 2 PO 4 , 300mMNaCl, pH 8.0) for washing at a flow rate of 2mL / min.

[0044] (3) After cleaning 8-10 column volumes, pass the obtained crude enzyme solution through the Ni-NTA column at a flow rate of 1 mL / min, and the target protein is mounted on the chromatography column. After loading, a large number of unadsorbed foreign proteins will not be bound to the resin and will be removed directly.

[0045] (4) Use equilibration buffer (50mM NaH 2 PO 4 , 300mM NaCl, 50mM imidazole, pH 8.0) to...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a nitrilase mutant and application thereof in preparation of 1-cyanocyclohexyl acetic acid. The nitrilase mutant is obtained by mutating one or more of 180th and 205th amino acids of an amino acid sequence shown as SEQ ID No.2. According to the invention, semi-rational design is adopted, proteins are subjected to molecular modification, the specific enzyme activity of nitrilase double mutant AcN-G180D / A205C is improved by 1.6 times to the maximum extent, the conversion rate is greater than 99%, and the reaction time is shortened to one fourth of the original reaction time by hydrolyzing 1-cyanocyclohexyl acetonitrile at a high temperature (50 DEG C) by using recombinant escherichia coli containing the nitrilase mutant. Therefore, the mutant obtained by the inventionhas a good application prospect in efficiently catalyzing the 1-cyanocyclohexyl acetonitrile to synthesize the gabapentin intermediate 1-cyanocyclohexyl acetic acid.

Description

[0001] (1) Technical field [0002] The invention relates to a mutant derived from the nitrilase of Acidovorax facilis CCTCC NO:M 209044 and its application in the preparation of antiepileptic drug gabapentin. [0003] (2) Background technology [0004] Gabapentin is an antiepileptic drug first developed by Warner-Lamber Company in the United States, and it was first launched in the UK in 1993. Gabapentin can prevent convulsions induced by some chemicals (such as picrotoxin, bicuculline, strychnine) and non-chemical stimuli (such as sound source, electric shock), and can prevent partial seizures and secondary generalized tonic-clonic convulsions. Seizures are effective. Compared with similar products currently used, it has fast oral absorption, good tolerance, less toxic and side effects, good therapeutic effect, no metabolism in the body, no binding with plasma proteins, no induction of liver enzymes, and the ability to pass through the blood of the human brain. Brain barrie...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N9/78C12N15/55C12N15/70C12N1/21C12P13/00
CPCC12N9/78C12Y305/05001C12N15/70C12P13/002C12N1/205C12R2001/19C12N2800/101
Inventor 薛亚平熊能李芊郑裕国
Owner ZHEJIANG UNIV OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap